In patients who met the criteria for prasugrel use recommended by the European Medicines Agency , thus excluding from the analysis patients with prior transient ischemic attack ( TIA ) / stroke , with weight < @ kg or age @ years , and censoring follow-up at @ days , ( European Union ( EU ) - label cohort ) prasugrel showed superiority over clopidogrel with regard to the primary endpoint ( HR @ , @ % CI @-@ @ , p < @ ) for the entire NSTE-ACS population , as well as for UA patients and NSTEMI patients without significant differences in non-CABG TIMI major bleeding .